Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Return on Sales (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Return on Sales for 16 consecutive years, with 1.01% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 169.0% to 1.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.01% through Dec 2025, up 169.0% year-over-year, with the annual reading at 1.01% for FY2025, 169.0% up from the prior year.
  • Return on Sales hit 1.01% in Q4 2025 for Perspective Therapeutics, up from 0.61% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 3.01% in Q2 2025 to a low of 2.37% in Q3 2022.
  • Historically, Return on Sales has averaged 0.17% across 5 years, with a median of 0.52% in 2022.
  • Biggest five-year swings in Return on Sales: crashed -204bps in 2024 and later skyrocketed 398bps in 2025.
  • Year by year, Return on Sales stood at 0.57% in 2021, then crashed by -140bps to 1.37% in 2022, then soared by 199bps to 1.36% in 2023, then crashed by -150bps to 0.67% in 2024, then soared by 250bps to 1.01% in 2025.
  • Business Quant data shows Return on Sales for CATX at 1.01% in Q4 2025, 0.61% in Q3 2025, and 3.01% in Q2 2025.